Back to Search
Start Over
Mesothelioma Biomarkers
- Source :
- Thoracic Surgery Clinics. 30:395-423
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- Malignant pleural mesothelioma (MPM) is an asbestos-related neoplasm that can only be treated successfully when correctly diagnosed and treated early. The asbestos-exposed population is a high-risk group that could benefit from sensitive and specific blood- or tissue-based biomarkers. We review recent work with biomarker development in MPM and literature of the last 20 years on the most promising blood- and tissue-based biomarkers. Proteomic, genomic, and epigenomic platforms are covered. SMRP is the only validated blood-based biomarker with diagnostic, monitoring and prognostic value. To strengthen development and testing of MPM biomarkers, cohorts for validation must be established by enlisting worldwide collaborations.
Details
- ISSN :
- 15474127
- Volume :
- 30
- Database :
- OpenAIRE
- Journal :
- Thoracic Surgery Clinics
- Accession number :
- edsair.doi...........0e5322e578412263a929c74928f4b271